<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03139006</url>
  </required_header>
  <id_info>
    <org_study_id>NL55917.041.16</org_study_id>
    <nct_id>NCT03139006</nct_id>
  </id_info>
  <brief_title>Application of speCtraL Computed tomogrAphy to impRove specIficity of Cardiac compuTed tomographY</brief_title>
  <acronym>CLARITY</acronym>
  <official_title>Diagnostic Accuracy of Spectral Computed Tomography for Detection of Flow Limiting Coronary Stenosis Using Fractional Flow Reserve as the Standard of Reference</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular disease remains the leading cause of morbidity and mortality worldwide.&#xD;
      Coronary computed tomography angiography (CCTA) and, if indicated, invasively measured&#xD;
      fractional flow reserve (FFR) is currently used for ruling out significant coronary artery&#xD;
      disease. FFRCT is a novel non-invasive technique in which FFR is derived from CT images,&#xD;
      however this method is currently, just like CCTA, lacking specificity. Spectral Detector CT&#xD;
      (SDCT) is a novel technique whereby a spectrum of monoenergetic images at different&#xD;
      kiloelectron Volt (keV) values (40 to 200 keV) can be reconstructed. By using these&#xD;
      monoenergetic images, a decrease in blooming and beam-hardening artifacts could be achieved.&#xD;
      In addition, SDCT offers the opportunity to assess myocardial iodine distribution and&#xD;
      quantification. When combining these factors, we hypothesize more accurate information will&#xD;
      be available about the coronary anatomy, degree of stenosis and FFRCT and thereby contribute&#xD;
      to a more accurate way for the detection of hemodynamic significant stenosis. Therefore, the&#xD;
      aim of this study is to assess the accuracy of SDCT as a non-invasive way for the detection&#xD;
      of hemodynamically significant coronary artery stenosis.&#xD;
&#xD;
      Objective: The overall objective of this project is to assess the accuracy of SDCT for the&#xD;
      detection of flow limiting stenosis in the coronary arteries using invasive FFR as the&#xD;
      standard of reference. Whereby different sub-aims (e.g. improvement of FFRCT) are made to&#xD;
      answer the overall objective. The secondary objective is to determine the decrease of calcium&#xD;
      blooming of calcifications and beam-hardening artifacts and the improvement of myocardial&#xD;
      blood volume quantification on SDCT in comparison with conventional CT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 29, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 29, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Flow limiting stenosis in the coronary arteries defined by invasive fractional flow reserve (FFR)</measure>
    <time_frame>within 30 days</time_frame>
    <description>An invasive FFR &lt;0.8 indicates a flow limiting stenosis</description>
  </primary_outcome>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Coronary Stenosis</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Cardiovascular Diseases</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dual-layer spectral detector CT</intervention_name>
    <description>A dual energy CT approach</description>
    <other_name>SDCT</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants ≥18 years of age with suspected or known stable angina with pre-test&#xD;
        likelihood of 50-85% for obstructive coronary disease (Eur Heart J 2013 guidelines on&#xD;
        stable CAD) and who are referred for clinical invasive FFR.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years old;&#xD;
&#xD;
          -  Suspected or known stable angina with pre-test likelihood of 50-85% for obstructive&#xD;
             coronary disease, using the method recommended by the European Society of Cardiology&#xD;
             2013 Guidelines on the management of stable coronary artery disease (Eur Heart J&#xD;
             2013);&#xD;
&#xD;
          -  Referred for invasive testing with fractional flow reserve;&#xD;
&#xD;
          -  Willing and able to give informed consent. The consent procedures, as set by the&#xD;
             Institutional Review Board (IRB) will be followed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with suspected or known stable angina with pre-test likelihood of 0-50% using&#xD;
             the method recommended by the European Society of Cardiology 2013 Guidelines on the&#xD;
             management of stable coronary artery disease (Eur Heart J 2013 [24]);&#xD;
&#xD;
          -  Subjects who because of age, general medical or psychiatric condition, or physiologic&#xD;
             status cannot give valid informed consent or tolerate the coronary CTA examination;&#xD;
&#xD;
          -  Subjects with (severe) renal insufficiency, indicated as glomerular filtration rate&#xD;
             (GFR) &lt;60 ml/min;&#xD;
&#xD;
          -  Subjects with unknown GFR or obtained &gt;3 months before the planned scan;&#xD;
&#xD;
          -  Contraindication or allergy to intravenous contrast agent(s);&#xD;
&#xD;
          -  Subjects who participate in an other study with radiation which is estimated to be in&#xD;
             risk category III (ICRP 62);&#xD;
&#xD;
          -  Subjects who are pregnant;&#xD;
&#xD;
          -  Subjects with contraindications to cardiac CT and/or S&amp;S protocol, intravenous&#xD;
             contrast, intravenous adenosine, betablockers or nitroglycerine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Leiner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robbert van Hamersvelt, MD</last_name>
    <phone>+31887550441</phone>
    <email>R.W.vanHamersvelt-3@umcutrecht.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tim Leiner, MD, PhD</last_name>
    <phone>+31887556687</phone>
    <email>T.Leiner@umcutrecht.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center UtrechtU</name>
      <address>
        <city>Utrecht</city>
        <zip>3508GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robbert van Hamersvelt, MD</last_name>
      <phone>+31887550441</phone>
      <email>R.W.vanHamersvelt-3@umcutrecht.nl</email>
    </contact>
    <investigator>
      <last_name>Tim Leiner, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robbert van Hamersvelt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>May 1, 2017</study_first_submitted>
  <study_first_submitted_qc>May 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2017</study_first_posted>
  <last_update_submitted>October 15, 2018</last_update_submitted>
  <last_update_submitted_qc>October 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Tim Leiner</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

